All IndicationsImmunology & InflammationPhase 3Phase 3Phase 3Phase 3Phase 3Phase 3Phase 2
🛡️
Psoriasis
5
Companies
8
Drug Programs
6
Phase 3
0
Upcoming PDUFAs
Competitors
TAK
Takeda
PsO pill
LLY
Eli Lilly and Company
Ixekizumab
LLY
Eli Lilly and Company
80 mg ixekizumab
AUPH
Aurinia Pharmaceuticals Inc.
Placebo
AUPH
Aurinia Pharmaceuticals Inc.
Ciclosporin
TAK
Takeda
zasocitinib
INCY
Incyte Corporation
Ruxolitinib phosphate cream
ABBV
AbbVie
Skyrizi
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| TAK Takeda | PsO pill | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Ixekizumab | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | 80 mg ixekizumab | Phase 3 | — | — | — |
| AUPH Aurinia Pharmaceuticals Inc. | Placebo | Phase 3 | — | — | — |
| AUPH Aurinia Pharmaceuticals Inc. | Ciclosporin | Phase 3 | — | — | — |
| TAK Takeda | zasocitinib | Phase 3 | — | — | — |
| INCY Incyte Corporation | Ruxolitinib phosphate cream | Phase 2 | — | — | — |
| ABBV AbbVie | Skyrizi | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
6
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.